<code id='4F0437DC34'></code><style id='4F0437DC34'></style>
    • <acronym id='4F0437DC34'></acronym>
      <center id='4F0437DC34'><center id='4F0437DC34'><tfoot id='4F0437DC34'></tfoot></center><abbr id='4F0437DC34'><dir id='4F0437DC34'><tfoot id='4F0437DC34'></tfoot><noframes id='4F0437DC34'>

    • <optgroup id='4F0437DC34'><strike id='4F0437DC34'><sup id='4F0437DC34'></sup></strike><code id='4F0437DC34'></code></optgroup>
        1. <b id='4F0437DC34'><label id='4F0437DC34'><select id='4F0437DC34'><dt id='4F0437DC34'><span id='4F0437DC34'></span></dt></select></label></b><u id='4F0437DC34'></u>
          <i id='4F0437DC34'><strike id='4F0437DC34'><tt id='4F0437DC34'><pre id='4F0437DC34'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:focus    - browse:656
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

          Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

          advertisement

          MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time